Stay updated with breaking news from Alberto Espay. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The first Alzheimer’s drugs meant to slow the progression of the fatal disease may only be available to a tiny fraction of patients, a study published Wednesday in the journal
The FDA has approved Leqembi, the first disease-modifying treatment for early-stage Alzheimer’s and a precursor condition, mild cognitive impairment. Medicare has said it will pay for the therapy. Medical centers
The FDA has approved Leqembi, the first disease-modifying treatment for early-stage Alzheimer’s and a precursor condition, mild cognitive impairment. Medicare has said it will pay for the therapy. Medical centers
Unanswered questions abound as this new era of treatment begins for mild cognitive impairment and early-stage Alzheimer’s.
Unanswered questions abound as this new era of treatment begins for mild cognitive impairment and early-stage Alzheimer’s.